A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria
NCT ID: NCT00843388
Last Updated: 2009-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2009-03-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
NCT04333823
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
NCT00378508
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
NCT03688711
The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
NCT01270191
Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
NCT04234867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
60 days treatment with tablet hexalacton 25 mg OD.
Spironolacton (hexalacton(R))
Tablet Spironolacton 25 mg OD
2
Inactive drug of 25 mg OD
placebo tablet
placebo tablet 25 mg OD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolacton (hexalacton(R))
Tablet Spironolacton 25 mg OD
placebo tablet
placebo tablet 25 mg OD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-80 years
* microalbuminuria
Exclusion Criteria
* persistent macroalbuminuria
* pregnancy or in risc of this
* P-Potassium\>5.7 mmol/l
* Eplerone treatment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steno Diabetes Center Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Steno Diabetes Center, Dep 520
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
stine e nielsen, MD
Role: PRINCIPAL_INVESTIGATOR
Steno Diabetes Center Copenhagen
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Eudra CT: 2008-004839-38
Identifier Type: -
Identifier Source: secondary_id
2306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.